Teva Pharmaceutical Industries ADR (TEVA)

$34.19 -0.24 (-0.70%)
Market Cap 39.31B
Revenue (ttm) 17.26B
Net Income (ttm) 1.41B
EPS (ttm) N/A
PE Ratio 12.21
Forward PE 14.58
Profit Margin 8.18%
Debt to Equity Ratio 2.02
Volume 5,713,300
Avg Vol 6,185,386
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 59%
Beta 0.84
Analysts Strong Sell
Price Target $39.45

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel
Johnnyvance
Johnnyvance Jun. 7 at 3:43 PM
$TEVA Surprised nobody has mentioned the Supreme Court skinny label ruling…. Big quiet win for teva
0 · Reply
Agent8
Agent8 Jun. 7 at 4:52 AM
$TEVA https://www.marketbeat.com/instant-alerts/filing-arrowpoint-investment-partners-singapore-pte-ltd-acquires-shares-of-152712-teva-pharmaceutical-industries-ltd-teva-2026-06-05/
0 · Reply
S2K_TP
S2K_TP Jun. 6 at 8:22 PM
$TEVA on the way 🔥🚨
0 · Reply
shoagh12
shoagh12 Jun. 5 at 11:21 AM
$TEVA
0 · Reply
cantpick4beans
cantpick4beans Jun. 4 at 3:35 PM
$TEVA
0 · Reply
TheDudeRooster
TheDudeRooster Jun. 4 at 1:54 PM
$TEVA Gotta love early morning scalps. Going to hit the sticks ✌️
0 · Reply
NoTradeAnymore
NoTradeAnymore Jun. 4 at 12:32 PM
$TEVA https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Expands-European-biosimilars-portfolio-with-launch-ofAHZANTIVEaflibercept-biosimilar-to-Eylea/default.aspx
0 · Reply
Menashes
Menashes Jun. 3 at 6:25 PM
$TEVA bullish
0 · Reply
Hopewisper
Hopewisper Jun. 3 at 4:52 PM
$TEVA Pick it up🌞
0 · Reply
Merlintrader
Merlintrader Jun. 3 at 11:11 AM
$TEVA UroGen Pharma (Nasdaq: $URGN) & Teva Pharmaceutical (NYSE: $TEVA): The JELMYTO Settlement, the 2030 Generic Window, ZUSDURI Launch Execution and Teva’s Pivot to Growth https://www.merlintrader.com/urogen-teva-litigation-june2026/
0 · Reply
Latest News on TEVA
TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease

2026-06-05T16:51:52.000Z - 2 days ago

TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

2026-06-05T15:46:00.000Z - 2 days ago

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets

2026-06-05T15:35:11.000Z - 2 days ago

Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea

2026-06-05T15:33:26.000Z - 2 days ago

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Fri, 05 Jun 2026 11:30:00 -0400 - 2 days ago

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva (TEVA) Launches New Biosimilar Ahzantive in Europe

2026-06-04T15:13:25.000Z - 3 days ago

Teva (TEVA) Launches New Biosimilar Ahzantive in Europe

Teva launches Ahzantive in Europe

2026-06-04T13:00:46.000Z - 3 days ago

Teva launches Ahzantive in Europe

Alvotech And Teva Resubmit BLAs To FDA For Biosimilars AVT05 And AVT06

2026-06-04T11:02:37.000Z - 3 days ago

Alvotech And Teva Resubmit BLAs To FDA For Biosimilars AVT05 And AVT06

Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but Still Overvalued -- GF Score: 55/100

2026-06-02T23:27:45.000Z - 5 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but Still Overvalued -- GF Score: 55/100

UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA)

2026-06-02T14:02:24.000Z - 5 days ago

UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA)

Teva to Present at the Goldman Sachs Global Healthcare Conference

Mon, 01 Jun 2026 16:30:00 -0400 - 6 days ago

Teva to Present at the Goldman Sachs Global Healthcare Conference

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

Mon, 01 Jun 2026 00:15:00 -0400 - 7 days ago

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

TEVA Partners with Veeva Systems for Global CRM Implementation

2026-05-27T12:28:15.000Z - 11 days ago

TEVA Partners with Veeva Systems for Global CRM Implementation

Teva commits to Veeva Vault CRM

2026-05-27T11:15:33.000Z - 11 days ago

Teva commits to Veeva Vault CRM

VEEV

Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749

2026-05-22T05:32:07.000Z - 17 days ago

Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749

TEVA Gains EMA Acceptance for New Schizophrenia Treatment

2026-05-21T17:50:47.000Z - 17 days ago

TEVA Gains EMA Acceptance for New Schizophrenia Treatment

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

2026-05-21T16:35:37.000Z - 17 days ago

Teva announces EMA acceptance of MAA for olanzapine long-acting injectable

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Thu, 21 May 2026 12:30:00 -0400 - 17 days ago

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Mon, 18 May 2026 08:30:00 -0400 - 20 days ago

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders

2026-05-18T12:26:38.000Z - 20 days ago

Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Mon, 18 May 2026 08:00:00 -0400 - 20 days ago

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd

2026-05-16T04:09:00.000Z - 23 days ago

Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.

Fri, 15 May 2026 01:00:00 -0400 - 24 days ago

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.

Teva put volume heavy and directionally bearish

2026-05-14T18:49:49.000Z - 24 days ago

Teva put volume heavy and directionally bearish

Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.

2026-05-14T08:56:00.000Z - 24 days ago

Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.

Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript

2026-05-12T23:00:28.000Z - 26 days ago

Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 12:20 PM EDT - 26 days ago

Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2026

Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)

2026-05-07T23:01:52.000Z - 4 weeks ago

Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Teva price target raised to $40 from $38 at Barclays

2026-05-07T10:11:42.000Z - 4 weeks ago

Teva price target raised to $40 from $38 at Barclays

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

2026-05-06T13:56:40.000Z - 4 weeks ago

Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

2026-05-05T21:06:13.000Z - 4 weeks ago

Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Teva to Present at the BofA Securities Health Care Conference

Mon, 04 May 2026 16:30:00 -0400 - 4 weeks ago

Teva to Present at the BofA Securities Health Care Conference

TEVA Maintained by JP Morgan -- Price Target Raised to $40.00

2026-05-01T00:01:08.000Z - 5 weeks ago

TEVA Maintained by JP Morgan -- Price Target Raised to $40.00

TEVA Maintained by UBS -- Price Target Raised to $42.00

2026-04-30T22:01:04.000Z - 5 weeks ago

TEVA Maintained by UBS -- Price Target Raised to $42.00

TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00

2026-04-30T18:36:45.000Z - 5 weeks ago

TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00

TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45

2026-04-30T16:33:14.000Z - 5 weeks ago

TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45

Teva price target raised to $50 from $45 at Goldman Sachs

2026-04-30T16:21:59.000Z - 5 weeks ago

Teva price target raised to $50 from $45 at Goldman Sachs

Teva price target raised to $40 from $35 at JPMorgan

2026-04-30T15:36:02.000Z - 5 weeks ago

Teva price target raised to $40 from $35 at JPMorgan

Teva price target raised to $42 from $41 at Piper Sandler

2026-04-30T12:49:01.000Z - 5 weeks ago

Teva price target raised to $42 from $41 at Piper Sandler

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Thu, 30 Apr 2026 08:30:00 -0400 - 5 weeks ago

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva price target raised to $42 from $36 at UBS

2026-04-30T10:56:16.000Z - 5 weeks ago

Teva price target raised to $42 from $36 at UBS

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

2026-04-30T08:44:00.000Z - 5 weeks ago

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 11.9% -- What GF Score of 58 Tells Investors

2026-04-29T22:21:37.000Z - 5 weeks ago

Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 11.9% -- What GF Score of 58 Tells Investors

Teva price target raised to $45 from $42 at Truist

2026-04-29T19:30:23.000Z - 5 weeks ago

Teva price target raised to $45 from $42 at Truist

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Wed, 29 Apr 2026 14:22:48 -0400 - 5 weeks ago

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Wed, 29 Apr 2026 13:52:33 -0400 - 5 weeks ago

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Unusually active option classes on open April 29th

2026-04-29T16:37:10.000Z - 5 weeks ago

Unusually active option classes on open April 29th

BBAI CVNA CVS FCEL JOBY NTLA PLUG

TEVA Forecasts Steady Revenue Growth and Strong Margins

2026-04-29T16:31:07.000Z - 5 weeks ago

TEVA Forecasts Steady Revenue Growth and Strong Margins

TEVA Expects Positive Impact from Emalex Acquisition

2026-04-29T16:29:34.000Z - 5 weeks ago

TEVA Expects Positive Impact from Emalex Acquisition

TEVA Forecasts $700 Million in Savings by 2027

2026-04-29T15:54:59.000Z - 5 weeks ago

TEVA Forecasts $700 Million in Savings by 2027

TEVA Positioned for Margin Growth and Strategic Moves

2026-04-29T15:51:43.000Z - 5 weeks ago

TEVA Positioned for Margin Growth and Strategic Moves

Teva Pharmaceutical Industries Transcript: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Transcript: M&A announcement

Teva Pharmaceutical Industries Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q1 2026

Teva Pharmaceutical Industries Slides: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Slides: M&A announcement

Teva Pharmaceutical Industries Press release: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Press release: M&A announcement

Teva Pharmaceutical Industries Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Slides: Q1 2026

Teva Pharmaceutical Industries Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Earnings release: Q1 2026

Teva Pharmaceutical Industries Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Teva Pharmaceutical Industries Quarterly report: Q1 2026

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Apr 29, 2026, 7:05 AM EDT - 5 weeks ago

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Apr 29, 2026, 7:00 AM EDT - 5 weeks ago

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Apr 29, 2026, 6:30 AM EDT - 5 weeks ago

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Apr 14, 2026, 8:00 AM EDT - 7 weeks ago

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Mar 30, 2026, 8:00 AM EDT - 2 months ago

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva Releases Q1 2026 Aide Memoire

Mar 19, 2026, 4:30 PM EDT - 2 months ago

Teva Releases Q1 2026 Aide Memoire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Mar 19, 2026, 4:30 PM EDT - 2 months ago

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference

Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:00 AM EDT - 3 months ago

Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026

Teva to Present at the Upcoming Investor Conferences in March

Feb 24, 2026, 4:30 PM EST - 3 months ago

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Feb 20, 2026, 2:43 PM EST - 3 months ago

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Teva Pharmaceutical Industries Transcript: Study result

Teva Pharmaceutical Industries Press release: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Teva Pharmaceutical Industries Press release: Study result

Teva Pharmaceutical Industries Slides: Study result

Feb 17, 2026, 8:00 AM EST - 3 months ago

Teva Pharmaceutical Industries Slides: Study result

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 3 months ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva Pharmaceutical Industries Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 9:30 AM EST - 4 months ago

Teva Pharmaceutical Industries Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Teva Pharmaceutical Industries Earnings Call Transcript: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q4 2025

Teva Pharmaceutical Industries Annual report: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Teva Pharmaceutical Industries Annual report: Q4 2025

Teva Pharmaceutical Industries Earnings release: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Teva Pharmaceutical Industries Earnings release: Q4 2025

Teva Pharmaceutical Industries Slides: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Teva Pharmaceutical Industries Slides: Q4 2025

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:31 AM EST - 4 months ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 28, 2026, 7:00 AM EST - 4 months ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 27, 2026, 8:00 AM EST - 4 months ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 5:02 PM EST - 5 months ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Teva Pharmaceutical Industries Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 5 months ago

Teva Pharmaceutical Industries Transcript: 44th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 5 months ago

Teva Pharmaceutical Industries Slides: 44th Annual J.P. Morgan Healthcare Conference

Why Investors Are So Optimistic on Teva

Jan 12, 2026, 10:46 AM EST - 5 months ago

Why Investors Are So Optimistic on Teva

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 6:00 PM EST - 5 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:00 PM EST - 5 months ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:30 PM EST - 5 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 24, 2025, 8:36 AM EST - 5 months ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 19, 2025, 3:40 AM EST - 6 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 9, 2025, 8:00 AM EST - 6 months ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Transcript: Citi Annual Global Healthcare Conference 2025

Dec 4, 2025, 10:30 AM EST - 6 months ago

Teva Pharmaceutical Industries Transcript: Citi Annual Global Healthcare Conference 2025

Teva Pharmaceutical Industries Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:00 AM EST - 6 months ago

Teva Pharmaceutical Industries Transcript: Piper Sandler 37th Annual Healthcare Conference

Teva Pharmaceutical Industries Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 8:20 AM EST - 6 months ago

Teva Pharmaceutical Industries Transcript: Evercore ISI 8th Annual HealthCONx Conference

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 25, 2025, 8:10 AM EST - 6 months ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 21, 2025, 4:30 PM EST - 7 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Teva seeks startups to help solve global pharmaceutical challenges

Nov 19, 2025, 8:07 AM EST - 7 months ago

Teva seeks startups to help solve global pharmaceutical challenges

Teva Pharmaceutical Industries Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 6:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Transcript: Jefferies London Healthcare Conference 2025

Teva Pharmaceutical Industries Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 8:45 AM EST - 7 months ago

Teva Pharmaceutical Industries Transcript: UBS Global Healthcare Conference 2025

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 7, 2025, 6:00 PM EST - 7 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:02 PM EST - 7 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 9:14 AM EST - 7 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Teva Pharmaceutical Industries Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q3 2025

Teva Pharmaceutical Industries Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Quarterly report: Q3 2025

Teva Pharmaceutical Industries Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Earnings release: Q3 2025

Teva Pharmaceutical Industries Slides: Q3 2025

Nov 5, 2025, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Slides: Q3 2025

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:44 AM EST - 7 months ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Nov 5, 2025, 7:00 AM EST - 7 months ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 31, 2025, 4:30 PM EDT - 7 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 30, 2025, 11:45 AM EDT - 7 months ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 20, 2025, 4:30 PM EDT - 8 months ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 10, 2025, 3:00 PM EDT - 8 months ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Teva Pharmaceutical Industries Transcript: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Teva Pharmaceutical Industries Transcript: Study Update

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 9 months ago

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 4:30 PM EDT - 9 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2025

Sep 24, 2025, 4:00 AM EDT - 9 months ago

Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2025

Teva Pharmaceutical Industries Transcript: Study Update

Sep 22, 2025, 11:00 AM EDT - 9 months ago

Teva Pharmaceutical Industries Transcript: Study Update

Teva Pharmaceutical Industries Press release: Study Update

Sep 22, 2025, 11:00 AM EDT - 9 months ago

Teva Pharmaceutical Industries Press release: Study Update

Teva Pharmaceutical Industries Slides: Study Update

Sep 22, 2025, 11:00 AM EDT - 9 months ago

Teva Pharmaceutical Industries Slides: Study Update

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 20, 2025, 10:15 PM EDT - 9 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 16, 2025, 4:30 PM EDT - 9 months ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva Pharmaceutical Industries Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 8:30 AM EDT - 9 months ago

Teva Pharmaceutical Industries Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Colorado must face Teva's lawsuit over free allergy pen law

Sep 5, 2025, 3:57 PM EDT - 9 months ago

Colorado must face Teva's lawsuit over free allergy pen law

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Sep 2, 2025, 4:30 PM EDT - 9 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 9:17 AM EDT - 10 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Johnnyvance
Johnnyvance Jun. 7 at 3:43 PM
$TEVA Surprised nobody has mentioned the Supreme Court skinny label ruling…. Big quiet win for teva
0 · Reply
Agent8
Agent8 Jun. 7 at 4:52 AM
$TEVA https://www.marketbeat.com/instant-alerts/filing-arrowpoint-investment-partners-singapore-pte-ltd-acquires-shares-of-152712-teva-pharmaceutical-industries-ltd-teva-2026-06-05/
0 · Reply
S2K_TP
S2K_TP Jun. 6 at 8:22 PM
$TEVA on the way 🔥🚨
0 · Reply
shoagh12
shoagh12 Jun. 5 at 11:21 AM
$TEVA
0 · Reply
cantpick4beans
cantpick4beans Jun. 4 at 3:35 PM
$TEVA
0 · Reply
TheDudeRooster
TheDudeRooster Jun. 4 at 1:54 PM
$TEVA Gotta love early morning scalps. Going to hit the sticks ✌️
0 · Reply
NoTradeAnymore
NoTradeAnymore Jun. 4 at 12:32 PM
$TEVA https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Expands-European-biosimilars-portfolio-with-launch-ofAHZANTIVEaflibercept-biosimilar-to-Eylea/default.aspx
0 · Reply
Menashes
Menashes Jun. 3 at 6:25 PM
$TEVA bullish
0 · Reply
Hopewisper
Hopewisper Jun. 3 at 4:52 PM
$TEVA Pick it up🌞
0 · Reply
Merlintrader
Merlintrader Jun. 3 at 11:11 AM
$TEVA UroGen Pharma (Nasdaq: $URGN) & Teva Pharmaceutical (NYSE: $TEVA): The JELMYTO Settlement, the 2030 Generic Window, ZUSDURI Launch Execution and Teva’s Pivot to Growth https://www.merlintrader.com/urogen-teva-litigation-june2026/
0 · Reply
john92
john92 Jun. 3 at 10:14 AM
$TEVA SCAM STOCK MARKET
0 · Reply
cantpick4beans
cantpick4beans Jun. 3 at 2:36 AM
$TEVA wtf
0 · Reply
Noname2022
Noname2022 Jun. 2 at 9:42 PM
$AKBA $TEVA Nothing says confidence in a branded franchise like the head of sales taking a job at Teva.
4 · Reply
tkstockpicker
tkstockpicker Jun. 2 at 7:41 PM
$TEVA yep what I want to see right here
0 · Reply
Menashes
Menashes Jun. 2 at 6:36 PM
$TEVA I was confident it would go up by the last close volumes. I was preparing to reenter here. Such a frustration. Weird movement btw.
0 · Reply
cantpick4beans
cantpick4beans Jun. 2 at 6:31 PM
$TEVA
0 · Reply
Terrordomo80
Terrordomo80 Jun. 2 at 3:58 PM
$TEVA You can do it #Dopewiser... #FearNot #JackOfAllMehoffs
1 · Reply
TheDudeRooster
TheDudeRooster Jun. 2 at 2:30 PM
$TEVA This could be juicy. Come on derivatives!!!
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 2 at 2:27 PM
$URGN This is not investment advice because we have no idea what will happen to UroGen. We'd only remind investors $ITCI announced they settled a similar patent dispute allowing Sandoz to market a generic Caplyta by 2040. ITCI announced the settlement 2 or 3 days before they announced they were being acquired by $JNJ Again, this is not investment advice. $TEVA can market a generic Jelmyto in 2030 which (most likely) limits Jelmyto's M&A valuation. Of course Zusduri is anticipated to outsell Jelmyto 7 or so to 1. Good luck
0 · Reply
TheDudeRooster
TheDudeRooster Jun. 2 at 2:18 PM
$TEVA Trying to enter for a scalp be like…
0 · Reply
Terrordomo80
Terrordomo80 Jun. 2 at 1:41 PM
$TEVA Zi Dopium always needs a little Zi Hopium... #HopeWiser #DopeWiser #BigDipper
0 · Reply
tkstockpicker
tkstockpicker Jun. 2 at 1:35 PM
$TEVA added
0 · Reply